Conference Coverage
Early MS biomarkers may improve prediction of long-term outcomes
Combining two biomarkers may shed more light on MS prognosis.
Conference Coverage
B-cell depletion overkill?
B-cell depletion following ocrelizumab or rituximab treatment often lasts longer than 6 months.
Conference Coverage
Home cognitive therapy looks feasible in MS
A randomized trial demonstrates how to deliver therapy at home.
Conference Coverage
DMTs tied to lower MS relapse during reproductive therapy
The likelihood of achieving pregnancy through assisted reproductive technologies while having MS appeared favorable.
Conference Coverage
MRI biomarker to be tested in MS
A new prospective trial aims to prove that central vein sign can distinguish MS from clinical mimics.
Expert Perspective
Do Not Expect a Patient With MS to Have Just MS
Conference Coverage
Ozanimod shows long-term safety, despite a pandemic
Open-label study confirms efficacy and COVID-19–related safety.
Conference Coverage
B-cell therapy for MS may impact COVID-19 vaccination
A prospective study found improved neutralizing antibody response with more time elapsed since therapy and vaccination.
Conference Coverage
Evidence mounts for paramagnetic rim lesions in diagnosing MS
The presence and number of iron rim lesions hold a prognostic value for long-term disability in MS.
Conference Coverage
Spinal cord atrophy predicts ‘silent progression’ in MS
This is a potentially important biomarker for disease progression that may otherwise go unrecognized by clinicians and patients.